Thursday, October 25th, 2:00-3:25pm
China has used Traditional Chinese Medicine (TCM) for centuries and still comprises a substantial portion of the Chinese healthcare industry. With Western pharmas beginning to show an appetite for these treatments, many in-licensing and co-development opportunities exist. How can Western companies incorporate TCM into their portfolios and what regulations govern these products in China and the West? What pharmaceutical and clinical research processes can companies pursue to further TCM and turn out global, innovative products? Biopharma executives from both China and the West will share their TCM strategies and current projects.
- Helen Chen, Director & Partner, L.E.K. Consulting
- Henry Sun, President & CEO, Tasly Pharmaceuticals, Inc.
- Xun Zhang, PhD, Vice President & Head of Innovative TCM Performance Discovery Unit, GlaxoSmithKline
- Jian-ping Zuo, PhD, Professor and Director of Department of Pharmacology, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences
Dr. Sun is the Vice President of China Tasly Group and co-founder and CEO of Tasly Pharmaceuticals Inc. of Maryland, USA. His responsibilities at these Corporations include managing all R&D activities, leading global regulatory and clinical programs, developing worldwide collaborations, investment and M&As, operating academic research and education programs, assisting international marketing, and designing quality control programs for the Corporation. In the past 5 years, Dr. Sun and group have successfully registered 20+ new drugs in 32 countries and completed the first-ever global phase II clinical trial for TCM and are now targeting worldwide phase III trials and registration at the US FDA. His view for Tasly Group is to bring this top 3 China based pharmaceutical company to be a global pharma within the next 5 years. Dr. Sun received his PhD degree from the University of Connecticut in 1993 and served as the Expert Regulatory Scientist at the FDA up to 2006 before his current position. Dr. Sun is also a Special Professor at University of Nottingham, School of Medicine.
Helen Chen is a director and partner of L.E.K. Consulting based in Shanghai. She is the co-head of the China office and a member of L.E.K.’s Global Leadership Team, the firm’s governing committee. Helen has over 20 years of consulting and industry experience in the U.S. and Asia, and has resided in China since 2000.
Helen is the head of L.E.K.’s China life sciences practice, with extensive case work and industry experience covering the full bio/pharmaceutical and medtech value chain, ranging from early research services to post-market product positioning and sales force effectiveness. She is on the Editorial Board of PharmAsia and on the Advisory Committee for BIO China. Helen is a sought after speaker and author on the opportunities and issues in the China healthcare and life sciences.
Prior to joining L.E.K., Helen held senior management roles at a number of technology companies in the U.S. and China. She was an associate director of finance at Genentech and a sales planner at Abbott Laboratories. She was on the Board of Pharmaceutical Management Sciences Association from 1995 to 1997, and was honored by Who’s Who Among American Women from 1993 to 1995.
Helen received her A.B. cum laude in applied mathematics from Harvard University.